Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Article in English | MEDLINE | ID: mdl-34738851

ABSTRACT

There are three types of autosomal recessive disorders involving pathogenic variants in the ALS2 gene (OMIM*606352), infantile ascending hereditary spastic paraplegia (IAHSP), juvenile primary lateral sclerosis (JPLS) and juvenile amyotrophic lateral sclerosis (JALS), which are rare and related to retrograde degeneration of motor neurons. ALS2 pathogenic variants are distributed widely across the entire coding sequence and mostly result in a loss of protein function. Rarely, patients with JALS have been reported with lower motor neuron involvement. Here, we report the first Brazilian cohort (six patients) of JPLS with novel ALS2 pathogenic variants, and we propose an expanding clinical and genetic spectrum of alsin-related disorders. A review of the literature in PubMed from 2001 to September 2020 allowed us to identify 26 publications about the three different phenotypes caused by ALS2 variants (only case reports or families), encompassing 35 nonrelated families. We compiled data (sex, age, age at onset, first symptoms, atypical clinical features, molecular data, and clinical evolution (improvement or death)) from these studies and analyzed them in a general context on the basis of demographic features.


Subject(s)
Amyotrophic Lateral Sclerosis , Motor Neuron Disease , Spastic Paraplegia, Hereditary , Amyotrophic Lateral Sclerosis/epidemiology , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/pathology , Brazil/epidemiology , Guanine Nucleotide Exchange Factors/genetics , Humans , Motor Neuron Disease/genetics , Spastic Paraplegia, Hereditary/genetics
2.
BMJ Case Rep ; 14(5)2021 May 11.
Article in English | MEDLINE | ID: mdl-33975845

ABSTRACT

Immune-mediated necrotising myopathy is a rare autoimmune myopathy characterised by severe progressive muscle weakness, elevated levels of creatine kinase (CK), and necrosis with minimal inflammatory cell infiltration on muscle biopsy. We report a case of a previously healthy 42-year-old woman who presented with progressive muscle weakness 2 weeks after immunisation for yellow fever, tetanus/diphtheria and hepatitis B. Her symptoms started from the lower limbs and progressed to the upper limbs and cervical region associated with dysphagia, making her wheelchair bound. Electromyography showed a myopathic pattern, with a CK level of 12.177 U/L (reference value: 26-190 U/L), and biceps brachial muscle biopsy confirmed necrosis and regeneration fibres. The immunoblot test was positive for antisignal recognition particle. She was successfully treated with prednisone (1 mg/kg/day). Although considered safe, vaccines may cause allergic reactions or trigger autoimmune disorders. Currently, a causal relationship between them cannot be established.


Subject(s)
Autoimmune Diseases , Muscular Diseases , Myositis , Adult , Autoimmune Diseases/diagnosis , Autoimmune Diseases/drug therapy , Creatine Kinase , Female , Humans , Muscular Diseases/chemically induced , Myositis/diagnosis , Myositis/etiology , Vaccination
3.
BMJ Case Rep ; 13(10)2020 Oct 08.
Article in English | MEDLINE | ID: mdl-33033004

ABSTRACT

Subacute symmetrical proximal muscle weakness and persistent elevated creatine kinase levels are typical of immune-mediated necrotising myopathy (IMNM). These conditions are accompanied by copious myofibre necrosis, degeneration and regeneration with minimal to no inflammation on muscle biopsy. We report two cases (case 1 and case 2) of asymptomatic IMNM from different families with hyperCKaemia associated with positive anti-signal recognition particle (SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies, respectively, and we also reviewed the literature. There are only a few previous descriptions of patients with asymptomatic IMNM.The disease onset could be insidious and lead to delayed diagnosis and treatment. We recommend testing for the anti-HMGCR and anti-SRP antibodies in patients with idiopathic hyperCKaemia because they could show no symptoms of this disorder.


Subject(s)
Autoantibodies/blood , Creatine Kinase/blood , Hydroxymethylglutaryl CoA Reductases/immunology , Immunoglobulins, Intravenous/administration & dosage , Myositis , Signal Recognition Particle/immunology , Asymptomatic Diseases , Biopsy/methods , Female , Humans , Immunologic Factors/administration & dosage , Male , Middle Aged , Muscle Weakness/diagnosis , Muscle Weakness/etiology , Muscle, Skeletal/pathology , Myositis/diagnosis , Myositis/immunology , Myositis/physiopathology , Necrosis/pathology , Treatment Outcome
4.
Parkinsons Dis ; 2019: 4951379, 2019.
Article in English | MEDLINE | ID: mdl-31871617

ABSTRACT

In the early sixties, a discussion started regarding the association between Parkinson's disease (PD) and type II diabetes mellitus (T2DM). Today, this potential relationship is still a matter of debate. This review aims to analyze both diseases concerning causal relationships and treatments. A total of 104 articles were found, and studies on animal and "in vitro" models showed that T2DM causes neurological alterations that may be associated with PD, such as deregulation of the dopaminergic system, a decrease in the expression of peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α), an increase in the expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 (PED/PEA-15), and neuroinflammation, as well as acceleration of the formation of alpha-synuclein amyloid fibrils. In addition, clinical studies described that Parkinson's symptoms were notably worse after the onset of T2DM, and seven deregulated genes were identified in the DNA of T2DM and PD patients. Regarding treatment, the action of antidiabetic drugs, especially incretin mimetic agents, seems to confer certain degree of neuroprotection to PD patients. In conclusion, the available evidence on the interaction between T2DM and PD justifies more robust clinical trials exploring this interaction especially the clinical management of patients with both conditions.

5.
Biomed Res Int ; 2013: 604635, 2013.
Article in English | MEDLINE | ID: mdl-23509749

ABSTRACT

INTRODUCTION: Several evidences show that muscles have an endocrine function. Glucocorticoid, estrogen, progesterone, and testosterone receptors have already been found in normal skeletal muscles, but not in dystrophic muscles. METHODS: The gene expression of hormone receptors was compared between dystrophic and healthy muscles in mdx and C57BL6 mice strains. RESULTS: The mdx mice showed a significant increase in the steroid receptors mRNA when compared to the C57BL6 mice: levels of androgen(s) receptors in the heart, estrogen receptors alpha in the EDL, and estrogen receptors beta in the quadriceps were increased. In addition, significant lowered levels of some other hormone receptors were found: corticosteroid receptors in the EDL and estrogen receptors alpha in the quadriceps. CONCLUSION: Dystrophic muscles bear significant differences in the expression of hormone receptors when compared to the C57BL6 mice strain. The importance of such differences is yet to be better understood.


Subject(s)
Gene Expression Regulation , Muscle, Skeletal/metabolism , Muscular Dystrophy, Animal/metabolism , Receptors, Androgen/metabolism , Receptors, Estrogen/metabolism , Animals , Disease Progression , Female , Male , Mice , Mice, Inbred C57BL , Mice, Inbred mdx , Myocardium/metabolism , RNA, Messenger/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...